Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com

Galectin Therapeutics (NASDAQ:GALT) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Monday.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, August 15th.

Galectin Therapeutics Price Performance

GALT stock traded down $0.09 on Monday, reaching $1.87. The company’s stock had a trading volume of 91,592 shares, compared to its average volume of 68,072. Galectin Therapeutics has a 52 week low of $1.02 and a 52 week high of $2.47. The company has a market capitalization of $115.66 million, a P/E ratio of -2.46 and a beta of 1.17. The firm has a fifty day moving average of $1.98 and a two-hundred day moving average of $1.72.

Institutional Investors Weigh In On Galectin Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GALT. PNC Financial Services Group Inc. lifted its position in Galectin Therapeutics by 21.7% in the first quarter. PNC Financial Services Group Inc. now owns 56,184 shares of the company’s stock worth $90,000 after purchasing an additional 10,000 shares during the period. Centaurus Financial Inc. acquired a new stake in Galectin Therapeutics in the first quarter worth approximately $34,000. Atria Wealth Solutions Inc. acquired a new stake in Galectin Therapeutics in the first quarter worth approximately $460,000. State Street Corp lifted its position in Galectin Therapeutics by 9.4% in the first quarter. State Street Corp now owns 173,740 shares of the company’s stock worth $280,000 after purchasing an additional 14,981 shares during the period. Finally, MML Investors Services LLC lifted its position in Galectin Therapeutics by 28.4% in the third quarter. MML Investors Services LLC now owns 49,777 shares of the company’s stock worth $81,000 after purchasing an additional 11,000 shares during the period. 12.24% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.